Trial to Evaluate Diarrhoea Discontinuations at 3 Cycles in Patients With Early-stage HER2+, HR+ Breast Cancer Treated With Neratinib Plus Loperamide Versus Neratinib Dose Escalation Plus Loperamide Administered as Needed Versus Neratinib Plus Loperamide Plus Colesevelam (DIANER)
Conditions: Early-stage Breast Cancer; HER2 Positive Breast Cancer; Hormone Receptor Positive Interventions: Drug: Neratinib; Drug: Loperamide; Drug: Colesevelam Sponsors: Spanish Breast Cancer Research Group; Puma Biotechnology, Inc.; Pierre Fabre Laboratories Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Biotechnology | Breast Cancer | Cancer | Cancer & Oncology | Diarrhoea | HER2 | Imodium | Loperamide | Research | Welchol